Polyclonal Antibody to Factor Related Apoptosis Ligand (FASL)
| Code | Size | Price |
|---|
| PAA031Hu01-20ul | 20ul | £66.00 |
Quantity:
| PAA031Hu01-100ul | 100ul | £115.00 |
Quantity:
| PAA031Hu01-200ul | 200ul | £150.00 |
Quantity:
| PAA031Hu01-1ml | 1ml | £330.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD178; CD95L; CD95-L; FASLG; FASLG; APT1LG1; APT1-LG1; TNFSF6; Fas Antigen Ligand; TNF Superfamily Member 6; Tumor Necrosis Factor(ligand)Superfamily,Member 6
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Factor Related Apoptosis Ligand
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:240-980<br/>Immunohistochemistry: 5-20ug/mL;1:24-98<br/>Immunocytochemistry: 5-20ug/mL;1:24-98<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Factor Related Apoptosis Ligand (FASL) | RPA031Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||